Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
A health ministry drug pricing panel kicked off its discussions on the proposed revamp of the drug pricing system on November 30, with members representing the industry and healthcare providers opposing annual price revisions. The launch of such discussions by…
To read the full story
Related Article
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
REGULATORY
- Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
- Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
- Chuikyo Payers Signal Mixed Views on Off-Year Drug Price Revisions
February 16, 2026
- Chuikyo Issues FY2026 Fee Revision Recommendation, Creates New Premiums for Generics and Biosimilars
February 16, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…